APYX News and Press, Apyx Medical Corporation From 01/10/23

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022. ...

APYX® MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVION® PR Newswire Direct-to-Consumer Marketing Shows How Results Can Be Achieved Using Minimally Invasive Technology CLEARWATER, Fla. , Jan. 3, 2023 /PRNewswire/ -- Apyx...

%ShelfOfferings (or shelf registrations as they’re sometimes called) have seem to making an appearance more frequently when sifting through headlines. This term may be new to some people, but essential it is a type of offering that allows an issuer some flexibility (time-wise) to...

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , announced today that management will participate in the Piper Sandler 34 th Annual Healt...

Apyx Medical Corporation (APYX) Q3 2022 Earnings Conference Call November 10, 2022 08:00 ET Company Participants Charles Goodwin - President and Chief Executive Officer Tara Semb - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-H...

Apyx Medical ( NASDAQ: APYX ) stock slumped ~64% on Thursday after Q3 results missed estimates and the company lowered its FY22 outlook. Net loss widened to -$5.8M, compared to -$4.23M in Q3 2021. Total revenue fell -23% Y/Y to $9.11M. Revenue from Advan...

Apyx Medical press release ( NASDAQ: APYX ): Q3 GAAP EPS of -$0.17 misses by $0.03 . Revenue of $9.1M (-23.1% Y/Y) misses by $2.91M . Adjusted EBITDA loss of $3.9 million, compared to adjusted EBITDA loss of $2.7 million for the third quarter of 2021. The...

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2022, and updated finan...

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the third quarter of fiscal year 2022 will be rel...

'BOTCHED' TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION® HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURES PR Newswire Doctors Attest to Advanced Energy Technology Device's Transformative Solutions to Achieve Desired Results in Pat...